We investigated the course of 54 patients presenting with primary central nervous system lymphoma, who were treated in daily practice. The patients were treated with chemotherapy and/or radiotherapy and/or intrathecal chemotherapy. At a median follow-up period of 23 months (range 1-71), median relapse-free survival (RFS) and overall survival (OS) were not reached. Estimated 2-year RFS and OS rates were 42% and 48%, respectively. Ten relapsed PCNSL patients underwent ASCT. Complete remission rate of these patients was 40%, with 20% treatment-related mortality. Estimated 2-year RFS and OS rates were 37% and 40%, respectively. The prognosis of patients with PCNSL, who received off-study treatment, is still dismal. (c) 2016 Elsevier Ltd. All rights reserved.
C1 [Erkurt, Mehmet Ali; Berber, Ilhami; Kaya, Emin; Kuku, Irfan] Inonu Univ, Fac Med, Dept Hematol, TR-44069 Malatya, Turkey.
[Tekgunduz, Emre; Altuntas, Fevzi; Dal, Mehmet Sinan] Ankara Oncol Hosp, Hematol & HCT Clin, Ankara, Turkey.
[Dogu, Mehmet Hilmi; Sari, Ismail] Pamukkale Univ, Fac Med, Dept Hematol, Denizli, Turkey.
[Korkmaz, Serdal] Kayseri Trainer & Res Hosp, Div Hematol, Kayseri, Turkey.
[Demir, Cengiz] Yuzuncu Yil Univ, Fac Med, Dept Hematol, Van, Turkey.
[Yilmaz, Mehmet] Antep Univ, Fac Med, Dept Hematol, Gaziantep, Turkey.
[Akay, Olga Meltem] Osmangazi Univ, Fac Med, Dept Hematol, Eskisehir, Turkey.
[Pala, Cigdem] Erciyes Univ, Fac Med, Dept Hematol, Kayseri, Turkey.
[Bilen, Yusuf] Ataturk Univ, Fac Med, Dept Hematol, Erzurum, Turkey.
[Sencan, Mehmet] Cumhuriyet Univ, Fac Med, Dept Hematol, Sivas, Turkey.
[Altuntas, Fevzi] Yildirim Beyazit Univ, Fac Med, Dept Internal Med, Div Hematol, Ankara, Turkey.
[Aydogdu, Ismet] Celal Bayar Univ, Fac Med, Dept Hematol, Manisa, Turkey.